Curaleaf International, a subsidiary of Curaleaf Holdings, Inc. (TSX:CURA), has officially introduced its Curaleaf-branded medical cannabis products in Australia. This launch expands Curaleaf’s footprint in one of the fastest-growing medical cannabis markets globally.
The initial offering includes four distinct strains of cannabis flower. Distribution will be managed through Canngea, a licensed manufacturer and wholesaler in Australia known for its expertise in the medical cannabis sector. This collaboration aligns with Curaleaf’s strategy to deliver high-quality products and services to patients and healthcare professionals in Australia.
Patients can expect a wider range of products in the upcoming months, including precision-dosed inhalation formats and popular strains already available in the UK, Germany, and other European countries. This move reflects the growing demand for medical cannabis in Australia, which is projected to exceed $1 billion in annual sales next year.
Juan Martinez, Head of Curaleaf International, highlighted the importance of this market entry, stating, “Expanding into Australia represents a key part of our global strategy to increase access to reliable cannabis medicines backed by evidence.” He emphasized Curaleaf’s commitment to supplying consistent, dependable products bolstered by a sophisticated supply chain.
Boris Jordan, Chairman and CEO of Curaleaf, noted that Australia presents an exciting opportunity for growth in the cannabis sector. He expressed confidence in Curaleaf’s established product portfolio and innovative approach, which will contribute to its goal of becoming the leading cannabis company worldwide.
Curaleaf International’s operations are supported by a robust supply chain that includes cultivation and processing facilities across Europe and Canada. The company prioritizes research and product quality, aiming to ensure that patients have access to safe and legal cannabis options. Its extensive network includes a UK clinic, a pharmacy, and a laboratory, as well as processing facilities in Portugal and Spain.
The introduction of Curaleaf’s products in Australia signifies a step forward in meeting the evolving needs of patients seeking medical cannabis solutions. As the market continues to grow, Curaleaf is poised to play a significant role in shaping the future of cannabis medicine in the region.
English 
Spanish 
German 
Czech